Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24 h in Healthy Japanese Subjects

INTRODUCTION: Latanoprostene bunod is a novel nitric oxide (NO)-donating prostaglandin F2α receptor agonist in clinical development for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. We evaluated the effect of latanoprostene bunod 0.024% inst...

Descripción completa

Detalles Bibliográficos
Autores principales: Araie, Makoto, Sforzolini, Baldo Scassellati, Vittitow, Jason, Weinreb, Robert N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662725/
https://www.ncbi.nlm.nih.gov/pubmed/26563323
http://dx.doi.org/10.1007/s12325-015-0260-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662725/
https://www.ncbi.nlm.nih.gov/pubmed/26563323
http://dx.doi.org/10.1007/s12325-015-0260-y

Ejemplares similares